Valuation: Celgene

Market Cap 77.04B 66.12B 62.06B 56.68B 107B 7,348B 107B 734B 285B 3,707B 289B 283B 12,277B P/E 2017
28.7x
P/E 2018 11.6x
Enterprise Value 91.26B 78.33B 73.52B 67.15B 127B 8,704B 127B 870B 337B 4,391B 343B 335B 14,544B EV / Sales 2017
6.61x
EV / Sales 2018 3.86x
Free-Float
-
Yield 2017 *
-
Yield 2018 -
15/06/23 Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation CI
08/09/21 Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation CI
22/06/21 Celgene Corporation Will Grant Sun Pharmaceutical Industries Limited A License to Celgene's Patents Required to Manufacture and Sell Certain Limited Quantity CI
23/02/21 Celgene Corporation Issues Notice of Redemption of Notes CI
04/02/21 Bristol-Myers Squibb Company and Celgene Corporation Announce Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion CI
05/01/21 Ikena Oncology, Inc. announced that it has received $120 million in funding from a group of investors CI
23/12/20 Amgen : Signs Licensing Agreement With Medicines Development for Global Health MT
06/11/20 Bristol Myers Squibb : Q3 Results Beat Estimates; Raises 2020 EPS Outlook MT
23/09/20 Silverback Therapeutics, Inc. announced that it has received $84.999996 million in funding from a group of investors CI
22/09/20 Silverback Therapeutics, Inc. announced that it expects to receive $84.999996 million in funding from a group of investors CI
26/03/20 Agios Pharmaceuticals, Inc. Provides Update on 2016 Collaboration Agreement with Celgene CI
11/03/20 Silverback Therapeutics, Inc. announced that it has received $68.400013 million in funding from a group of investors CI
05/03/20 Pulmonary Fibrosis Foundation Launches Industry Consortium to Identify Biomarkers in Pulmonary Fibrosis CI

Financials

2017 2018
Net sales 13B 11.16B 10.48B 9.57B 18.06B 1,240B 18.14B 124B 48.04B 626B 48.82B 47.76B 2,072B 15.28B 13.12B 12.31B 11.24B 21.22B 1,457B 21.32B 146B 56.46B 735B 57.38B 56.13B 2,435B
Net income 2.94B 2.52B 2.37B 2.16B 4.08B 280B 4.1B 28.03B 10.86B 141B 11.04B 10.8B 469B 4.05B 3.47B 3.26B 2.98B 5.62B 386B 5.65B 38.57B 14.95B 195B 15.19B 14.86B 645B
Net Debt 3.79B 3.26B 3.06B 2.79B 5.27B 362B 5.29B 36.16B 14.01B 183B 14.24B 13.93B 604B 14.22B 12.21B 11.46B 10.46B 19.75B 1,356B 19.84B 136B 52.54B 684B 53.4B 52.24B 2,266B
Logo Celgene
Celgene Corporation specializes in the design, development, and sale of products for treating cancer and immune system disorders. Net sales break down by product family as follows: - therapeutic products (99.9%); - other (0.1%): cellular therapy products and biological materials for implants, for tissue and organ treatments, and for therapeutic product development. Net sales are distributed geographically as follows: the United States (65.6%), Europe (24.7%) and other (9.7%).
Employees
-
Sector
-
  1. Stock Market
  2. Stocks
  3. CELG Stock